China Pharmaceuticals and Healthcare Report Q2 2012
NEW YORK, April 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
China Pharmaceuticals and Healthcare Report Q2 2012
http://www.reportlinker.com/p0184082/China-Pharmaceuticals-and-Healthcare-Report-Q2-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Includes 3 FREE quarterly updates
BMI View: 2012 is a very important year for the country as the government look to carry on their
achievements following the healthcare reform in 2009. We highlight that the expansion of the National
Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceutical
companies especially domestic firms while multinationals will benefit from the increase in medical
insurance coverage in the National Drug Reimbursement List. China's 12th five-year healthcare plan, if
executed smoothly, will allow the country to maintain its position as the world's most attractive emerging
pharmaceutical market.
Headline Expenditure Projections
- Pharmaceuticals: CNY432bn (US66.7bn) in 2011to CNY520bn (US$81.3bn) in 2012; +20.4%
in local currency and +21.6% in US dollar terms.
- Healthcare: CNY1,876bn (US$290bn) in 2011 to CNY2,073bn (US$324bn) in 2012; +10.5%
in local currency terms and +16.6% in US dollar terms.
- Medical Devices: CNY140bn (US$21.6bn) in 2011 to CNY158bn (US$24.7bn) in 2012;
+13.3% in local currency terms and +14.5% in US dollar terms.
Risk/Reward Rating: China's score of 62.5 is a decline from Q112, causing it to slip in ranking from
fourth on our proprietary index to fifth, ahead of Taiwan but behind Singapore. The country lags behind
Singapore in terms of per-capita pharmaceutical and health expenditure.
Key Trends And Developments
- In February 2012, Pfizer signed a framework agreement with Chinese company Zhejiang Hisun
Pharmaceutical to set up a joint venture (JV) to develop, produce and commercialise generic
pharmaceutical products in China and other markets. According to the agreement, the JV will be
called Hisun Pfizer Pharmaceutical, with Hisun owning 51% and Pfizer owning 49%. The
aggregate investment and registered capital will total US$295mn and US$250mn respectively.
Both parties could contribute some existing products, cash, manufacturing sites and other assets
after the formation of the JV, which is subject to closing conditions, including the approval of the
authorities in China.
- In January 2012, the State Food and Drug Administration approved Novartis' wet (neovascular)
age-related macular degeneration (AMD) treatment Lucentis (ranibizumab). Wet AMD causes
blindness and severe vision loss in patients over 50 and there are about 300,000 new cases
diagnosed a year in China alone. Novartis will also launch its oral type 2 diabetes treatment
Galvus (vildagliptin) in China as an additional medication to complement metformin. Type 2
diabetes affects 75mn Chinese people; more than in any other country. The release of both
treatments indicates Novartis' commitment to providing innovative healthcare solutions to
emerging markets.
BMI Economic View: The spike is China's headline consumer price inflation figure in January to 4.5%
year-on-year (y-o-y), while a concern, appears to mask the underlying trend of disinflation evident in core
inflation and producer price inflation. With money supply growth still historically weak, and housing
market weakness gathering pace, we maintain our average CPI forecast of 3.1% for 2012, and still see
two 25 basis points interest rate cuts as growth and inflation fall further.
BMI Political View: China faces myriad economic, social and environmental challenges over the coming
decades that could seriously test the Communist Party's ability to govern. The best-case scenario for any
eventual political transition would entail an elite-led liberalisation of the authoritarian system, while the
worst case scenario would involve a violent change of regime.
Executive Summary . 5
SWOT Analysis . 7
China Pharmaceuticals And Healthcare Industry SWOT .. 7
China Political SWOT ... 8
China Economic SWOT . 9
China Business Environment SWOT .. 9
Pharmaceutical Risk/Reward Ratings .. 10
Table: Asia Pacific Pharmaceutical And Healthcare RRRs, Q212 .. 10
Rewards ... 11
Risks 11
China – Market Summary .. 12
Regulatory Regime . 14
Intellectual Property Issues . 16
Counterfeit Medicines .. 18
Pricing Regime 19
Price Cuts 20
Reimbursement Regime 22
Industry Trends and Developments . 24
Epidemiology ... 24
Communicable Diseases .. 25
Non-Communicable Diseases .. 25
Healthcare Sector 27
Hospital Sector 28
R&D Activity 29
Selected List Of MNC With R&D Bases In China 30
Clinical Trials Activity . 32
Biotechnology Sector ... 34
Active Pharmaceutical Ingredients .. 36
Vaccine Sector . 37
Industry
Forecast Scenario
... 39
Overall Market Forecast.. 39
Table: Pharmaceutical Sales Indicators 2008-2016 40
Key Growth Factors – Industry 41
Table: Healthcare Expenditure Indicators 2008-2016 . 41
Table: Healthcare Governmental Indicators 2008-2016 . 42
Table: Healthcare Private Indicators 2008-2016 42
Key Growth Factors – Macroeconomic Forecast 44
Table: China – Economic Activity, 2011-2016 47
Prescription Drug Market Forecast . 48
Table: Prescription Drug Sales Indicators 2008-2016 49
Patented Drug Market Forecast .. 50
Table: Patented Drug Market Indicators 2008-2016 ... 51
Generic Drug Market Forecast 52
Table: Generic Drug Sales Indicators 2008-2016 ... 53
OTC Medicine Market Forecast .. 54
Table: OTC Medicine Sales Indicators 2008-2016 .. 56
Medical Device Market Forecast . 57
Table: Medical Devices Sales Indicators, 2008-2016 .. 59
Pharmaceutical Trade Forecast .. 60
Table: Exports and Imports Indicators 2008-2016 .. 61
Other Healthcare Data Forecasts 62
Key Risks To BMI's
Forecast Scenario
62
Competitive Landscape . 64
Pharmaceutical Industry .. 64
Top 20 China Or Hong Kong-Based Pharmaceutical Companies According To Market Capitalisation . 64
Recent Pharmaceutical Industry Developments ... 65
Traditional Chinese Medicine .. 66
Company Profiles ... 70
Leading Local Companies 70
Sinopharm 70
China Shijiazhuang Pharmaceutical Group (CSPC) ... 72
North China Pharmaceutical Corporation (NCPC) . 74
Hubei Biocause Pharmaceutical .. 76
Shanghai Pharmaceutical 78
Leading Multinational Companies 80
GlaxoSmithKline .. 80
Pfizer ... 82
AstraZeneca . 85
Merck KGaA 88
Sanofi ... 90
Novartis ... 92
Roche ... 95
Eli Lilly (Lilly China) ... 97
Merck & Co . 99
Bayer Schering Pharma ..101
Country Snapshot: China Demographic Data ... 104
Section 1: Population ..104
Table: Demographic Indicators, 2005-2030 ...104
Table: Rural/Urban Breakdown, 2005-2030 ..105
Section 2: Education and Healthcare .105
Table: Education, 2002-2005 .105
Table: Vital Statistics, 2005-2030 ...105
Glossary 106
BMI Methodology . 108
How We Generate Our Pharmaceutical Industry Forecasts 108
Risk/Reward Ratings Methodology .109
Ratings Overview 109
Table: Pharmaceutical Business Environment Indicators ..110
Weighting 111
Table: Weighting Of Components ...111
To order this report:
Drug and Medication Industry: China Pharmaceuticals and Healthcare Report Q2 2012
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article